儿童重症监护病房金黄色葡萄球菌感染中万古霉素和利奈唑胺最低抑菌浓度变化趋势研究OA

OBJECTIVE:To analyze the correlations between the minimum inhibitory concentration(MIC)and clinical outcomes as well as blood drug concentration monitoring results,and to provide a theoretical basis for optimizing the application of antibacterial drugs and improving clinical efficacy.METHODS:Clinical data of 87 pediatric patients with Staphylococcus aureus infections treated with vancomycin in the pediatric intensive care unit(PICU)of our hospital from January 1,2018,to December 31,2024,were retrospectively collected and analyzed.RESULTS:Methicillin-resistant S.aureus(MRSA)strains accounted for 64.1%of all isolates,while the methicillin-sensitive S.aureus(MSSA)accounted for 35.9%,and the detection rate of MRSA showed a general downward trend.No vancomycin-resistant strains were identified,and the average vancomycin MIC was 0.866 μg/mL.No MIC creep was observed during the study,although a gradual increase in linezolid MIC was noted from 2018 to 2023.The average treatment duration for MRSA infection is higher than that for MSSA infection,and the hospitalization time shows the same trend.The average blood concentration of vancomycin in patients with MIC<0.5 μ g/mL was higher than that in patients with MIC of 1 μg/mL and 2 μg/mL.CONCLUSIONS:Continuous monitoring of MIC trends and blood drug concentrations of vancomycin is essential for optimizing anti-infective therapy and preventing treatment failure,especially in pediatric patients with high vancomycin MIC levels.